Navigation Links
ReGen to FDA: 'Thanks, But No Thanks'
Date:3/22/2011

WASHINGTON, March 22, 2011 /PRNewswire/ -- ReGen Biologics, Inc. (ReGen), manufacturer of the popular and successful Menaflex Collagen Meniscus implant, today declined the U.S. Food and Drug Administration's (FDA) offer of a hearing under 21 CFR Part 16 before the agency formalizes its decision to rescind clearance of the device.

According to ReGen Chair and CEO Gerald E. Bisbee, Jr., Ph.D., the company's experience with the FDA over the past six years makes it clear that any such hearing would be futile. "The safety and effectiveness issues surrounding the clearance of our device were settled years ago at a November 14, 2008 Advisory Panel meeting.  The independent experts on that Panel were completely in Menaflex's favor," he said.  "The only issues that require remediation are the blatantly arbitrary and unfair processes of the FDA, and those aren't on the table in a Part 16 review.  Enough is enough."

ReGen's Menaflex device is a resorbable surgical mesh used in meniscus surgeries to reinforce damaged or weakened meniscal soft tissues, which provides a scaffold for replacement by a patient's own soft tissue.  It was approved in Europe in 2000 under the most stringent review classification for use in medial meniscus injuries, and in 2006 for lateral meniscus injuries.  To date, the device has been used successfully in over 3000 European surgeries, with no safety issues.  In fact, a recent independent publication from a prestigious European academic center shows that 10 years after surgery, Menaflex patients show superiority to patients receiving the standard of care, partial meniscectomy.

In December 2008, following 3 years of review under the 510(k) process including input from an Advisory Panel of independent experts, the FDA ruled that the product is as safe and effective as other surgical meshes and cleared it for use by surgeons in the U.S.  Two years later, following a change in top management at FD
'/>"/>

SOURCE ReGen Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
5. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the OARSI 2007 World Congress on Osteoarthritis
6. Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinsons Disease
7. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
8. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
9. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
10. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
11. International Team Locates Key Player in Muscle Regeneration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... May 27, 2015 ... the addition of the  "2015 Strategies in ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... strategic overview of the orthopedics market, including ... and product categories. , ,In addition, the ...
(Date:5/27/2015)... , May 27, 2015 ... has announced the addition of the  "North ... Forecasts (2014 - 2019)"  report to ... ,  , ,Mammography is a detailed type ... system to inspect breasts. A mammography exam, ...
(Date:5/27/2015)... -- OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to ... series of diverse complications arising from the presence of ... which cause a rapidly progressing hyperactive host immune response ... depending on disease severity. The syndrome places a major ... marketplace, which for the purposes of this report is ...
Breaking Medicine Technology:Global Orthopedics Market Strategies 2015 2North America Mammography Market - Growth, Trends And Forecasts (2014 - 2019) 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4
... SILVER SPRING, Md., May 6, 2011 The U.S. Food ... allow a new group of patients at risk of stroke ... RX Acculink carotid stent. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... neck bring blood to the brain. The blood flow in ...
... BEACH, Calif., May 6, 2011 Yesterday, the ... Novartis drug Afinitor® (everolimus) for the treatment of ... less than five percent of all pancreatic cancer ... aggressive than the more common form of pancreatic ...
Cached Medicine Technology:FDA Expands Approved Use For Carotid Stent 2FDA Expands Approved Use For Carotid Stent 3FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors 2
(Date:5/27/2015)... 27, 2015 Ticket Down is a reputable source ... Cavs have been super hot during the 2014-15 NBA season and ... points with a final score of 118-88. , For ... Finals since 2006-2007 when they lost to the San Antonio Spurs. ... chances of the Cavaliers making it to the NBA finals increased ...
(Date:5/27/2015)... New York, New York (PRWEB) May 27, 2015 ... http://www.risperdallawsuit2014.com/ ) filed on behalf of individuals ... other complications related to the use of the ... mass tort litigation currently underway in Pennsylvania’s Philadelphia ... the litigation is proceeding with its bellwether trial ...
(Date:5/27/2015)... San Marcos, CA (PRWEB) May 27, 2015 ... a solution to help patients - who need extensive dental ... as well as treatment options customized for their problems. , ... consists in a visual presentation of the assessment of the ... most suitable options, which can treat their oral health problems. ...
(Date:5/27/2015)... 27, 2015 In support of a ... issue of the Journal of American Geriatrics Society about ... obesity, Bedford Commons OB-GYN P.A . is reiterating ... sweetener-flavored beverages. , To examine the relationship between ... San Antonio Longitudinal Study of Aging (SALSA) tracked the ...
(Date:5/27/2015)... NY (PRWEB) May 27, 2015 Difass ... launched in the U.S. with its first three flagship ... available for purchase nationwide through http://www.difassusa.com . ... person’s health and productivity, but some people struggle with ... night. Dormiva™ is a sleep aid designed to help ...
Breaking Medicine News(10 mins):Health News:Cavs NBA Finals Tickets: Ticket Down Slashes Ticket Prices on Cleveland Cavaliers 2015 NBA Finals Tickets at Quicken Loans Arena and Offers Valuable Promo Code 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 3Health News:San Marcos Dentistry Office Offering a New Service Dental Case Planning 2Health News:Recent Study About the Link Between Diet Sodas and Abdominal Fat Reinforces Bedford Commons OB-GYN's Recommendation to Drink Plenty of Water 2Health News:Supplement Brand Difass USA Launches in the U.S. with Three Flagship Products Designed to Bring Balance Back to Your Life 2
... announces the world’s first genetically altered chicken eggs that can be ... ,Scientists of the Roslin Institute at Edinburgh, Scotland ... lay eggs that can be used to create life saving drugs. ... of a fraction of what the National Health Service incurs, according ...
... a source of bone for grafting may avoid the complications ... according to a report in the November/December issue //of The ... bone could become the new standard for harvesting bone grafts ... Polley and colleagues of Rush University Medical Center, Chicago. ...
... another gene responsible for late-onset Alzheimer’s disease. This is ... around 90 percent of patients) and develops after 65 ... of Toronto, and Columbia University have discovered the gene ... ,The reasearchers spent five years locating the ...
... to conduct a bigger trial of a vaccine against the ... substantially increased survival time for many. // ,The vaccine ... who had responded to conventional treatment and suggested that the ... the cancer, reported the online edition of BBC News. ...
... at the Vanderbilt Kennedy Center for Research on Human ... to cocaine and behavioral //and neurological problems in the ... of Neuroscience, Gregg Stanwood, Ph.D., and Pat Levitt, Ph.D., ... cocaine in rabbits, which caused a prolonged displacement of ...
... new study by researchers at the University of Minnesota Medical ... of fast food are more likely to have unhealthy eating ... higher risk for obesity. The study results were published ... ,The Study finds that the home food environment of ...
Cached Medicine News:Health News:No Pills Just Omelets 2Health News:New Technique Uses Pubic Bone for Grafting 2Health News:New Gene to Help in Understanding Alzheimer’s Diseas 2Health News:Cocaine During Pregnancy can Cause Behavioral and Neurological Problems in the Child 2Health News:Cocaine During Pregnancy can Cause Behavioral and Neurological Problems in the Child 3Health News:Fast Food Limits Healthy Food Intake, Increases Obesity Risk 2
SHIONORIA BNP,is a reagent used in the measurement of blood BNP. The blood BNP test allows accurate estimation of coronary functions....
The Elisa test is used for the detection and semi-quantitative determination of IgG, antibodies to myeloperoxidase in human sera as an aid to the diagnosis is of microscopic polyangiitis....
... of this Enzyme ImmunoAssay (EIA) is as ... immobilised on a 96 well microtiter plate. ... washing, the trapped molecule is covalently linked ... groups. After washing and denaturing treatment, Angiotensin ...
... a solid phase two-site enzyme immunoassay. ... sandwich technique in which two monoclonal ... determinants on the insulin molecule. During ... with peroxidase-conjugated anti-insulin antibodies and anti-insulin ...
Medicine Products: